$124.67−0.16 (−0.13%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Protagonist Therapeutics (PTGX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
14 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 89% below its peak, net margin −282.8%. Worth your attention in FY25: Share count (+37.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼89.4%
46.0
FY21→FY25CAGR +13.9%/yr
Net income ($M)—
−130.1
FY21→FY25CAGR —
Free cash flow ($M)▼69.3%
56.1
FY21→FY25CAGR —
Diluted EPS—
−2.05
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+37.2%
46.3mn → 63.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$1.6M
+17.3% YoY in FY25 · 3.5% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-283¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Net margin -282.8% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 551,690.0 | 46,016.0 | 434,433.0 | 60,000.0 | 26,581.0 | 27,357.0 | ▼89.4% | +13.9% |
Cost of revenue | 1,100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 550,590.0 | —A | —A | —A | —A | 27,357.0 | — | — |
Research & development | 176,432.0 | 159,290.0 | 138,128.0 | 120,161.0 | 126,215.0 | 126,006.0 | ▲15.3% | +6.0% |
Selling, general & admin | 51,063.0 | 44,853.0 | 43,462.0 | 33,491.0 | 31,739.0 | 27,196.0 | ▲3.2% | +13.3% |
Total operating expenses | 227,495.0 | 204,143.0 | 181,590.0 | 153,652.0 | 157,954.0 | 153,202.0 | ▲12.4% | +7.4% |
Operating incomefeeds ROC rank | 323,095.0 | −158,127.0 | 252,843.0 | −93,652.0 | −131,373.0 | −125,845.0 | — | — |
Other income, net | 27,153.0 | 28,816.0 | 26,565.0 | 14,697.0 | 3,980.0 | 294.0 | — | — |
Pretax income | 350,248.0 | −129,311.0 | 279,408.0 | −78,955.0 | −127,393.0 | −125,551.0 | — | — |
Income tax | 7,985.0 | 838.0 | 4,220.0 | 0.0 | 0.0 | — | ▼80.1% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | 342,263.0 | −130,149.0 | 275,188.0 | −78,955.0 | −127,393.0 | −125,551.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 4.72 | −2.05 | 4.23 | −1.39 | −2.60 | −2.71 | — | — |
Diluted shares (mn) | 71.73 | 63.57 | 65.08 | 56.76 | 49.04 | 46.32 | ▼2.3% | +8.2% |
| Margins | ||||||||
Gross margin99th pct in Healthcare | 99.8% | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | 58.6% | −343.6% | 58.2% | −156.1% | −494.2% | −460.0% | ▼401.8pp | +116.4pp |
Net margin100th pct in Healthcare | 62.0% | −282.8% | 63.3% | −131.6% | −479.3% | −458.9% | ▼346.2pp | +176.1pp |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Protagonist Therapeutics' revenue last fiscal year?
Protagonist Therapeutics reported revenue of $46.0M in fiscal 2025, down 89.4% from fiscal 2024.
What was Protagonist Therapeutics' net income?
Protagonist Therapeutics reported net income of −$130.1M in fiscal 2025, a net margin of −282.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

